Canaccord Genuity analyst Max Masucci reiterated a Buy rating on Exact Sciences (EXAS – Research Report) on January 13 and set a price target of $120.00. The company’s shares closed last Monday at $89.69.
Currently, the analyst consensus on Exact Sciences is a Strong Buy with an average price target of $123.56, a 32.4% upside from current levels. In a report issued on January 10, BTIG also initiated coverage with a Buy rating on the stock with a $127.00 price target.
Based on Exact Sciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $40.46 million. In comparison, last year the company had a GAAP net loss of $53.97 million.
Based on the recent corporate insider activity of 44 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EXAS in relation to earlier this year. Most recently, in December 2019, Kevin T. Conroy, the President & CEO of EXAS bought 11,440 shares for a total of $199,992.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the early detection of colorectal cancer and pre-cancer. The company was founded on February 10, 1995 and is headquartered in Madison, WI.